SG11201901689YA - Compounds for treating diseases associated with a mitochondrial dysfonction - Google Patents
Compounds for treating diseases associated with a mitochondrial dysfonctionInfo
- Publication number
- SG11201901689YA SG11201901689YA SG11201901689YA SG11201901689YA SG11201901689YA SG 11201901689Y A SG11201901689Y A SG 11201901689YA SG 11201901689Y A SG11201901689Y A SG 11201901689YA SG 11201901689Y A SG11201901689Y A SG 11201901689YA SG 11201901689Y A SG11201901689Y A SG 11201901689YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- paris
- mitochondrial
- dysfonction
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000002438 mitochondrial effect Effects 0.000 title abstract 2
- 230000004065 mitochondrial dysfunction Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306094.0A EP3290039B1 (en) | 2016-08-30 | 2016-08-30 | Compounds for treating diseases associated with a mitochondrial dysfonction |
| PCT/EP2017/071812 WO2018041919A1 (en) | 2016-08-30 | 2017-08-30 | Compounds for treating diseases associated with a mitochondrial dysfonction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901689YA true SG11201901689YA (en) | 2019-03-28 |
Family
ID=56896495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901689YA SG11201901689YA (en) | 2016-08-30 | 2017-08-30 | Compounds for treating diseases associated with a mitochondrial dysfonction |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10857135B2 (enExample) |
| EP (2) | EP3290039B1 (enExample) |
| JP (1) | JP7065854B2 (enExample) |
| KR (1) | KR20200011927A (enExample) |
| CN (1) | CN110035758B (enExample) |
| AU (1) | AU2017317651B2 (enExample) |
| BR (1) | BR112019004236A2 (enExample) |
| CA (1) | CA3034694A1 (enExample) |
| ES (1) | ES2800917T3 (enExample) |
| MA (1) | MA46099A (enExample) |
| MX (1) | MX394782B (enExample) |
| RU (1) | RU2019108824A (enExample) |
| SG (1) | SG11201901689YA (enExample) |
| WO (1) | WO2018041919A1 (enExample) |
| ZA (1) | ZA201900997B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3290039B1 (en) * | 2016-08-30 | 2020-03-25 | Amabiotics | Compounds for treating diseases associated with a mitochondrial dysfonction |
| JP2021517124A (ja) * | 2018-03-07 | 2021-07-15 | エーエムエーバイオティクス | アルツハイマー病を治療するための化合物 |
| US20220096574A1 (en) * | 2019-01-29 | 2022-03-31 | Holobiome, Inc. | Methods and compositions for treating and preventing central nervous system disorders and other conditions caused by gut microbial dysbiosis |
| EP4028014A1 (en) * | 2019-09-12 | 2022-07-20 | Stellate Therapeutics | Compounds for treating neurodegenerative diseases |
| WO2021048431A1 (en) * | 2019-09-12 | 2021-03-18 | Amabiotics | Compounds for treating ataxia |
| CN116850191A (zh) * | 2023-06-16 | 2023-10-10 | 山东大学齐鲁医院 | 奎因在制备治疗线粒体功能障碍相关疾病药物中的应用 |
| WO2026057085A1 (zh) * | 2024-09-15 | 2026-03-19 | 澳门科技大学 | Queuine在抗衰老中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5936615A (ja) * | 1982-08-24 | 1984-02-28 | Takeda Chem Ind Ltd | 発がん予防剤 |
| US6020139A (en) * | 1995-04-25 | 2000-02-01 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| JPH11506426A (ja) * | 1995-04-25 | 1999-06-08 | オリディグム コーポレイション | 代謝経路のｓ−アデノシルメチオニン調節ならびに診断および治療におけるその使用 |
| FR3002139B1 (fr) * | 2013-02-21 | 2015-06-19 | Amabiotics | Utilisation cosmetique de la queuine |
| GB201417163D0 (en) * | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases |
| GB201417165D0 (en) | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Treatments for Autoimmune Disease |
| EP3290039B1 (en) * | 2016-08-30 | 2020-03-25 | Amabiotics | Compounds for treating diseases associated with a mitochondrial dysfonction |
-
2016
- 2016-08-30 EP EP16306094.0A patent/EP3290039B1/en active Active
- 2016-08-30 ES ES16306094T patent/ES2800917T3/es active Active
-
2017
- 2017-08-30 KR KR1020197008753A patent/KR20200011927A/ko not_active Abandoned
- 2017-08-30 AU AU2017317651A patent/AU2017317651B2/en not_active Expired - Fee Related
- 2017-08-30 WO PCT/EP2017/071812 patent/WO2018041919A1/en not_active Ceased
- 2017-08-30 EP EP17771680.0A patent/EP3506903A1/en not_active Withdrawn
- 2017-08-30 CA CA3034694A patent/CA3034694A1/en active Pending
- 2017-08-30 RU RU2019108824A patent/RU2019108824A/ru unknown
- 2017-08-30 SG SG11201901689YA patent/SG11201901689YA/en unknown
- 2017-08-30 CN CN201780053445.8A patent/CN110035758B/zh active Active
- 2017-08-30 US US16/328,784 patent/US10857135B2/en active Active
- 2017-08-30 MA MA046099A patent/MA46099A/fr unknown
- 2017-08-30 BR BR112019004236A patent/BR112019004236A2/pt not_active IP Right Cessation
- 2017-08-30 MX MX2019002369A patent/MX394782B/es unknown
- 2017-08-30 JP JP2019532202A patent/JP7065854B2/ja active Active
-
2019
- 2019-02-15 ZA ZA2019/00997A patent/ZA201900997B/en unknown
-
2020
- 2020-11-02 US US17/086,583 patent/US11684611B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019004236A2 (pt) | 2019-05-28 |
| JP2019526634A (ja) | 2019-09-19 |
| EP3290039A1 (en) | 2018-03-07 |
| AU2017317651B2 (en) | 2022-12-15 |
| US20210046056A1 (en) | 2021-02-18 |
| CN110035758A (zh) | 2019-07-19 |
| US10857135B2 (en) | 2020-12-08 |
| MA46099A (fr) | 2019-07-10 |
| MX394782B (es) | 2025-03-24 |
| ZA201900997B (en) | 2020-05-27 |
| ES2800917T3 (es) | 2021-01-05 |
| US11684611B2 (en) | 2023-06-27 |
| RU2019108824A (ru) | 2020-10-01 |
| CA3034694A1 (en) | 2018-03-08 |
| MX2019002369A (es) | 2019-11-07 |
| JP7065854B2 (ja) | 2022-05-12 |
| KR20200011927A (ko) | 2020-02-04 |
| EP3506903A1 (en) | 2019-07-10 |
| EP3290039B1 (en) | 2020-03-25 |
| CN110035758B (zh) | 2023-06-16 |
| RU2019108824A3 (enExample) | 2020-12-31 |
| WO2018041919A1 (en) | 2018-03-08 |
| AU2017317651A1 (en) | 2019-03-07 |
| US20190224174A1 (en) | 2019-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201901633WA (en) | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201810123SA (en) | Treatment of intrahepatic cholestatic diseases |